The resveratrol/Sirtris/GSK saga — direct SIRT1 activation is largely an assay artifact
Sinclair's early fame came from resveratrol activating the "longevity gene" SIRT1; he co-founded Sirtris, which GSK bought for ~$720M in 2008. But Amgen and Pfizer found the compounds activate SIRT1 only when the test uses a fluorophore-tagged substrate — an in-vitro artifact; with native substrates, no direct activation. GSK terminated the lead compound (SRT501) in 2010 and shut Sirtris in 2013. Oral resveratrol also has very low bioavailability, and a human caloric-restriction-mimic RCT found no CR signature.
Sinclair's scientific reputation was first built on the claim that resveratrol — a compound found in red wine — directly activates SIRT1, a "longevity gene" whose activation was proposed to mimic the lifespan- extending effects of caloric restriction. This work drove the founding of Sirtris Pharmaceuticals, which GlaxoSmithKline acquired for approximately $720 million in 2008 on the strength of the SIRT1-activation thesis. The mechanism did not hold up: independent investigations at Amgen and Pfizer found that the original assays showing SIRT1 activation depended on a fluorophore-tagged substrate used in the screening method — an artifact of the assay chemistry, not a biological effect. When native, untagged substrates were used, no direct SIRT1 activation was observed. GSK terminated its lead compound, SRT501, in 2010 after disappointing clinical results and safety concerns, and shut down Sirtris entirely in 2013. Separate from the mechanism question, oral resveratrol also has very low bioavailability in humans, and a subsequent RCT looking for a caloric- restriction-mimetic signature in humans taking resveratrol found none.
Why it matters (spine): this is the field's clearest, most expensive, most publicly documented example of a longevity mechanism story outrunning the underlying biology — a nine-figure pharma acquisition collapsing when independent labs couldn't replicate the core assay result. It is the canonical reference case for what "hype" looks like when it has real money and real institutions behind it, not just a marketing claim.
Live status / Provenance: the assay-artifact findings and their fallout are documented across multiple sources including Nature Biotechnology coverage (18 Mar 2013) of the Sirtris shutdown; the Amgen and Pfizer replication failures were separately published and are part of the standard scientific record on this episode. Sirtris was co-founded by David A. Sinclair; GSK's ~$720M acquisition and subsequent 2013 closure are matters of public corporate record.
So we should carry this case forward as the reference example every time a new "activates your longevity genes" claim appears — treat such claims as unproven until independently replicated with native substrates and physiologically relevant doses, exactly as this episode should have been treated at the time.
Use this as the canonical "label the hype" case: a $720M acquisition built on a mechanism that didn't replicate. Treat any "X activates your longevity genes" supplement claim as guilty until independently proven.
domains: longevity · hype · sirtuins · pharma